Results: 3

1.
FIGURE 2.

FIGURE 2. From: Armodafinil for Treatment of Excessive Sleepiness Associated With Shift Work Disorder: A Randomized Controlled Study.

Mean sleep latency on the Multiple Sleep Latency Test (MSLT). Sleep latency by visit for the last 4 tests (2-8 am) (left) and during the final visit night shift (midnight to 8 am) (right). Error bars indicate SEM. P values are based on the change from baseline compared with placebo. *P<.001, †P<.01, and ‡P<.05.

Charles A. Czeisler, et al. Mayo Clin Proc. 2009 November;84(11):958-972.
2.
FIGURE 3.

FIGURE 3. From: Armodafinil for Treatment of Excessive Sleepiness Associated With Shift Work Disorder: A Randomized Controlled Study.

Mean Karolinska Sleepiness Scale (KSS) scores. Scores are by visit (A) and during the final visit night shift (midnight to 8 am) (B); for quality of episodic secondary memory by visit (C) and during the final visit night shift (midnight to 8 am) (D); for delayed word recall accuracy by visit (E) and during the final visit night shift (midnight to 8 am) (F); for power of attention by visit (G) and during the final visit night shift (midnight to 8 am) (H); and for simple reaction time by visit (I) and during the final visit night shift (midnight to 8 am) (J) compared with placebo. Data presented over time are during the final visit night shift. Error bars indicate SEM. P values are based on the change from baseline compared with placebo. *P≤.001, †P≤.01, ‡P<.05.

Charles A. Czeisler, et al. Mayo Clin Proc. 2009 November;84(11):958-972.
3.
FIGURE 1.

FIGURE 1. From: Armodafinil for Treatment of Excessive Sleepiness Associated With Shift Work Disorder: A Randomized Controlled Study.

Patient disposition. Screened patients include patients referred from central advertising, investigators' advertising effort, and investigators' patients. Reasons patients were not randomized include the following: sleep efficiency of more than 87.5%, n=117; consent withdrawn, n=106; met exclusion criteria, n=67; clinically significant, uncontrolled medical or psychiatric condition, n=11; diagnosis of a sleep disorder other than shift work disorder (SWD), n=20; average daily caffeine consumption >600 mg/d, n=1; use of disallowed prescription or over-the-counter medications, n=10; history of substance abuse, n=2; positive urinary drug screen result at screening, n=27; disorder that may interfere with drug absorption, distribution, metabolism, or excretion, n=1; other (undetermined), n=1; mean sleep latency time greater than 6 minutes, n=45; lost to follow-up, n=36; patient in poor health, n=23; patient unable to comply with protocol, n=18; insufficient shift work exposure, n=16; patient does not meet clinical severity criteria, n=10; patient does not meet criteria for SWD diagnosis or excessive sleepiness, n=5; presence of another medical or psychiatric disorder that could account for the excessive sleepiness, n=4; adverse event, n=2; reason not provided, n=2; and other, n=55. Randomized patients who received at least 1 dose of drug and had a baseline and at least 1 postbaseline assessment for the Multiple Sleep Latency Test and Clinical Global Impressions of Improvement were included in efficacy analyses.

Charles A. Czeisler, et al. Mayo Clin Proc. 2009 November;84(11):958-972.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk